Hyperhomocysteinemia Genotyping for Thrombotic Risk Assessment - DISCONTINUED
Homocysteine genotyping, MTHFR genotyping, Hyperhomocysteinemia genotyping, Hyperhomocysteinemia (MTHFR) Genotyping
Effective Date: 1/24/2022
Testing recommendations for MTHFR mutations have evolved and the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG) recommend against testing due to lack of predictive value for venous thromboembolism (VTE) or adverse pregnancy outcomes. There is growing evidence that disproves an association between hyperhomocysteinemia and risk for coronary heart disease and between MTHFR polymorphism status and risk for venous thromboembolism.
1. ACMG Practice Guideline in Genetics in Medicine 2013; 15:153-156.
2. ACOG Practice Bulletin Summary. Obstetrics & Gynecology 2018; 132: 249-251.
Due to these factors MTHFR genotyping will be discontinued and no Send Outs options are offered through Beaumont Laboratory.
Both Factor V Leiden (Test Code: LAB6383; CPT Code: 81241) and Factor II (Prothrombin) genotyping (Test Code: 6389; CPT Code: 81240) will continue to be offered at Beaumont Laboratory.
Hyperhomocysteinemia Genotyping for Thrombotic Risk Assessment (Homocysteine genotyping, MTHFR genotyping, Hyperhomocysteinemia genotyping, Hyperhomocysteinemia (MTHFR) Genotyping).
Test Code: LAB6386 CPT: 81291
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.